Immediate Impact
68 standout
Citing Papers
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Why do patients with cancer die?
2024 Standout
Works of Showkat Bashir being referenced
Prospective study of the antitumor efficacy of long‐term octreotide treatment in patients with progressive metastatic gastrinoma
2002
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Showkat Bashir | 308 | 394 | 49 | 286 | 15 | 436 | |
| Jeremiah V. Ojeaburu | 310 | 404 | 39 | 296 | 7 | 422 | |
| Matilde Pia Spampatti | 285 | 309 | 83 | 198 | 14 | 425 | |
| Valentina Sciola | 319 | 367 | 96 | 228 | 18 | 507 | |
| Jeffrey A. Norton | 263 | 351 | 122 | 218 | 10 | 465 | |
| Johanna M. Zuetenhorst | 302 | 381 | 44 | 309 | 15 | 460 | |
| L Piscitelli | 337 | 377 | 53 | 246 | 12 | 428 | |
| Jerome Zacks | 378 | 442 | 36 | 351 | 14 | 510 | |
| Caroline Lopez | 301 | 364 | 38 | 266 | 22 | 408 | |
| Barbro Eriksson | 283 | 294 | 47 | 233 | 14 | 375 | |
| S. Nasoni | 321 | 349 | 20 | 221 | 8 | 373 |
All Works
Login with ORCID to disown or claim papers
Loading papers...